This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 25.15% and 67.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
by Zacks Equity Research
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $3.76, moving +0.53% from the previous trading session.
Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $3.49, marking a +0.58% move from the previous day.
New Strong Buy Stocks for July 7th
by Zacks Equity Research
ADMA, APOG, KIND, JBL and OII have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2023.
Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication
by Zacks Equity Research
Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.
CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why
by Zacks Equity Research
Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
by Zacks Equity Research
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug
by Zacks Equity Research
Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
by Zacks Equity Research
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
by Zacks Equity Research
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.
Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia
by Zacks Equity Research
Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.
Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate
by Zacks Equity Research
Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.
Denali (DNLI) Provides Update on Hunter Syndrome Study
by Zacks Equity Research
Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
by Zacks Equity Research
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal
by Zacks Equity Research
Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.
Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS
by Zacks Equity Research
Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.
GSK Announces Extension of FDA Review for Rare Blood Therapy
by Zacks Equity Research
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
by Zacks Equity Research
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.